Report : Europe Immunodiagnostics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product [Enzyme-Linked Immunosorbent Assays (ELISA), Chemiluminescence Immunoassays (CLIA), Radioimmunoassays (RIA), and Others], Clinical Indication (Infectious Diseases, Hepatitis+HIV, Endocrinology, Gastrointestinal, Metabolics, and Others), and End User (Hospitals, Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Others)     

At 7.2% CAGR, the Europe Immunodiagnostics Market is speculated to be worth US$ 8,686.76 million by 2028, says Business Market Insights

According to Business Market Insights’ research, the Europe immunodiagnostics market was valued at US$ 5,734.92 million in 2022 and is expected to reach US$ 8,686.76 million by 2028, registering an annual growth rate of 7.2% from 2022 to 2028.  Increasing prevalence of infectious diseases and increasing use of point-of-care immunodiagnostics are the critical factors attributed to the Europe immunodiagnostics market expansion.                 

The diagnosis and management of several ever-growing infectious disease caused by infectious agents such as viruses, fungi, bacteria, parasites, or their toxic products are surging number of prescriptions for immunodiagnostic tests, e.g., complement fixation, precipitation tests, agglutination tests, line blot assays, western blot assays, enzyme immunoassays (EIA), and immunofluorescence tests. For instance, according to the World Health Organization (WHO), approximately 58 million people worldwide suffer from chronic hepatitis C infection, with 1.5 million new conditions occurring every year. About 3.2 million adolescents and children have this infection. Diagnostics play a vital role in determining the direction of any medical treatment. Immunodiagnostics help diagnose diseases that severely impact the immune system. The facts mentioned above indicate that the rising prevalence of infectious diseases lead to the surging Europe immunodiagnostics market growth.

On the contrary, inadequate reimbursement scenario hurdles the growth of Europe immunodiagnostics market.    

Based on product, the Europe immunodiagnostics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassay (RIA), and others. The enzyme-linked immunosorbent assays (ELISA) segment held 55.4% market share in 2022, amassing US$ 3,179.01 million. It is projected to garner US$ 4,767.35 million by 2028 to expand at 7.0% CAGR during 2022–2028.  

Based on clinical indication, the Europe immunodiagnostics market is segmented into infectious diseases, hepatitis+HIV, endocrinology, gastrointestinal, metabolics and others. The infectious diseases segment held 44.7% market share in 2022, amassing US$ 2,563.33 million. It is projected to garner US$ 4,010.55 million by 2028 to expand at 7.7% CAGR during 2022–2028.

Based on end user, the Europe immunodiagnostics market is segmented into hospitals, clinics, diagnostics laboratories, academic and research institutes, and others. The hospital segment held 43.4% market share in 2022, amassing US$ 2,489.26 million. It is projected to garner US$ 3,714.06 million by 2028 to expand at 6.9% CAGR during 2022–2028.

Based on country, the Europe immunodiagnostics market is segmented into Germany, France, Italy, UK, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 29.5% market share in 2022. It was assessed at US$ 1,688.93 million in 2022 and is likely to hit US$ 2,500.92 million by 2028, exhibiting a CAGR of 6.8% during the forecast period.  

Key players dominating the Europe immunodiagnostics market are Abbott Laboratories; bioMerieux SA; Danaher Corp; DiaSorin S.p.A.; F. Hoffmann-La Roche Ltd; PerkinElmer Inc.; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthineers AG; Svar Life Science AB; and Thermo Fisher Scientific Inc among others.  

  • In 2021, Siemens Healthineers announced that Atellica VTLi Patient-Side Immunoassay Analyzer has obtained a CE mark. The Atellica VTLi analyzer provides lab standard, high-sensitivity cardiac troponin I (hs-cTnI) test results to clinicians in eight minutes using a patient's fingerstick blood sample. This has expedited the diagnosis of heart attack with Atellica VTLi Patient-Side Analyzer for industry first fingerstick high-sensitivity troponin I at Point-of-Care.

Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id:

Download Free PDF Brochure